MedTrace Logo

Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab

NCT01382407 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2017-04-27

No results posted yet for this study

Summary

The hypothesis of this study is that patients who suffered from acne vulgaris during adolescence are at greater risk of developing acneiform skin rash due to cetuximab.

Conditions

  • Colorectal Cancer Metastatic

Interventions

DRUG

Cetuximab

Once a week:Loading dose-400 mg/m2;subsequent-250 mg/m2 on days 8,15, 22,29,36 if administered as a single agent, or together with Irinotecan 125 mg/m2 on days 1,8,15,29 followed by administration every 42 days.

Sponsors & Collaborators

  • Merck KGaA, Darmstadt, Germany

    collaborator INDUSTRY

  • Rambam Health Care Campus

    lead OTHER

Principal Investigators

  • Gil Bar-Sela, M.D. · Rambam Health Care Campus

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2017-04-01
Completion
2017-04-01

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01382407 on ClinicalTrials.gov